Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QQRS | ISIN: US92765F1084 | Ticker-Symbol: RYI
Tradegate
20.11.24
21:15 Uhr
0,140 Euro
-0,004
-2,78 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
VIRACTA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VIRACTA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1400,14713:02
0,1400,14712:47

Aktuelle News zur VIRACTA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
VIRACTA THERAPEUTICS Aktie jetzt für 0€ handeln
FrVIRX stock touches 52-week low at $0.15 amid market challenges1
FrVIRX-Aktie erreicht 52-Wochen-Tief bei 0,15 US-Dollar-
13.11.Viracta Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary2
13.11.Viracta Therapeutics GAAP EPS of -$0.27 misses by $0.031
13.11.Viracta Therapeutics, Inc.: Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update526- Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report...
► Artikel lesen
07.11.Viracta begins 2nd round of layoffs in 3 months to keep lymphoma program afloat3
06.11.Viracta Therapeutics cuts workforce to focus on cancer program2
06.11.Viracta Therapeutics, Inc. - 8-K, Current Report-
23.08.Viracta Therapeutics stock hits 52-week low at $0.278
18.08.Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out1.228LONDON (dpa-AFX) - This week, once again, companies across the biotech sector continued to re-evaluate their pipelines and trim their workforces in a bid to conserve cash and extend their financial...
► Artikel lesen
14.08.Viracta reports progress in PTCL treatment trial9
14.08.Why Is Cancer-Focused Penny Stock Viracta Therapeutics Trading Higher On Wednesday?5
14.08.Viracta lays off 23% of staff, pauses program to slim down for race to finish line in lymphoma4
14.08.Why Is Viracta Therapeutics (VIRX) Stock Up 42% Today?4
14.08.Viracta jumps after corporate update4
14.08.Viracta Therapeutics GAAP EPS of -$0.25 beats by $0.111
14.08.Viracta Therapeutics, Inc. - 8-K, Current Report-
14.08.Viracta Therapeutics, Inc.: Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update170- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val's substantial...
► Artikel lesen
14.08.Viracta Therapeutics, Inc.: Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan91- New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val's substantial...
► Artikel lesen
20.06.Viracta Therapeutics, Inc. - 8-K, Current Report3
Seite:  Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1